Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cytokinetics (CYTK) received FDA approval to add Phase 3 MAPLE-HCM data comparing MYQORZO with metoprolol to its U.S. prescribing information.
The trial compared the drugs as single therapies in adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition involving thickened heart muscle that obstructs blood flow. MYQORZO met the primary endpoint of change in peak oxygen uptake from baseline to Week 24, measuring exercise capacity, and significantly improved five of six secondary endpoints. Overall adverse-event rates were similar between groups; hypertension occurred in 15% of MYQORZO patients versus 3% receiving metoprolol.
The update adds comparative evidence, not a new indication. MYQORZO remains approved for adults with symptomatic disease to improve functional capacity and symptoms, with an existing boxed warning for heart failure and restricted distribution requiring monitoring.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointPrimary endpoint met: change in peak oxygen uptake from baseline to Week 24, consistent across prespecified subgroups.
- Moderate pointFDA approval adds MAPLE-HCM comparative data against metoprolol to MYQORZO’s U.S. label.
- Moderate pointFive of six secondary endpoints significantly improved, covering functional class, symptoms, cardiac biomarkers and heart measurements.
Negative
- Moderate pointHypertension occurred in 15% versus 3% with metoprolol in MAPLE-HCM; overall adverse-event rates were similar.
Key Figures
- Primary endpoint assessment
- Week 24
- MAPLE-HCM primary endpoint of change in pVO2 was met
- Secondary endpoints improved
- 5 of 6
- MAPLE-HCM; improvements were significant
- Hypertension
- 15% vs 3%
- MYQORZO vs metoprolol in MAPLE-HCM
- LVEF initiation threshold
- <55%
- Initiation of MYQORZO is not recommended below this LVEF
- LVEF dose-reduction range
- <50% and ≥40%
- Decrease the MYQORZO dose in this range
- LVEF treatment-interruption threshold
- <40%
- Interrupt MYQORZO at this LVEF threshold
Previous Clinical trial Reports
-
MAPLE-HCM met its primary peak oxygen uptake endpoint versus metoprolol in topline results.
-
Additional MAPLE-HCM analysis found peak oxygen uptake improvements versus metoprolol across prior beta-blocker use.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sndA regulatory
lvef medical
rems regulatory
pvo2 medical
boxed warning regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is indicated for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.
“People living with HCM deserve treatment decisions grounded in rigorous evidence. For decades, beta-blockers have been a cornerstone of treatment for oHCM in the absence of rigorously conducted clinical trials demonstrating their utility in this condition,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In MAPLE-HCM, MYQORZO demonstrated significantly greater improvements in exercise capacity, symptom burden and cardiac biomarkers compared to metoprolol. MYQORZO is now the only cardiac myosin inhibitor with evidence comparing its effectiveness to a beta-blocker for the treatment of oHCM in its U.S. label, providing cardiologists and patients important information to inform treatment decisions.”
MYQORZO was approved by the FDA in December 2025 for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms based on the results from SEQUOIA-HCM, the pivotal, randomized, placebo-controlled, Phase 3 clinical trial of MYQORZO in patients with oHCM on background therapy. It is also approved for the treatment of patients with oHCM in China, European Union, United Kingdom and Canada.
The full U.S. Prescribing Information for MYQORZO includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients LVEF <
About MAPLE-HCM
MAPLE-HCM was a Phase 3, multi-center, randomized, double-blind, double-dummy, controlled clinical trial that compared MYQORZO to the standard-of-care beta-blocker metoprolol on peak oxygen uptake (pVO2). The results showed that MYQORZO met the primary endpoint of change in pVO2 from baseline to Week 24, an effect that was consistent across all prespecified subgroups, including in patients who were newly diagnosed or treatment naïve.1
MYQORZO also significantly improved five of six secondary endpoints, including New York Heart Association (NYHA) Functional Class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), NT-proBNP, post-Valsalva left ventricular outflow tract gradient (LVOT-G) and left atrial volume index (LAVI).
Overall, the rate of adverse events (AEs) was similar between groups. The most common AE reported in excess (>
About MYQORZO® (aficamten)
MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.2
Aficamten was studied in ACACIA-HCM, a completed, randomized, placebo-controlled, Phase 3clinical trial of aficamten in patients with nHCM. Aficamten is also under clinical investigation in CEDAR-HCM in a pediatric population with oHCM. Safety and efficacy of aficamten have not been established in a pediatric patient population. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.
IMPORTANT SAFETY INFORMATION
| WARNING: RISK OF HEART FAILURE |
| MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. |
| Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF < |
| Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS Program. |
CONTRAINDICATIONS
MYQORZO is contraindicated with concomitant use of rifampin.
WARNING AND PRECAUTIONS
Heart Failure
MYQORZO reduces cardiac contractility, which can reduce LVEF and cause heart failure.
Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, new or uncontrolled atrial fibrillation) may be at greater risk of developing systolic dysfunction and heart failure.
Assess patients’ clinical status and LVEF prior to and during treatment and adjust the MYQORZO dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide may be signs and symptoms of heart failure.
Initiation of MYQORZO in patients with LVEF <
MYQORZO REMS Program
MYQORZO is available only through a restricted program called the MYQORZO REMS Program, because of the risk of heart failure due to systolic dysfunction.
Notable requirements of the MYQORZO REMS Program include:
- Prescribers must be certified by enrolling in the MYQORZO REMS Program
- Patients must enroll in the MYQORZO REMS Program and comply with ongoing monitoring requirements
- Pharmacies must be certified by enrolling in the MYQORZO REMS Program and must only dispense to patients who are authorized to receive MYQORZO
- Wholesalers and distributors must only distribute to certified pharmacies
Further information is available at www.MYQORZOREMS.com, or at 1-844-285-7367.
Cytochrome P450 Interactions Leading to Heart Failure or Loss of Effectiveness
MYQORZO is metabolized primarily by CYP2C9, and to a lesser extent by CYP3A, CYP2D6, and CYP2C19 enzymes. Initiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (eg, fluconazole, voriconazole, or fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction. Conversely, initiation of medications that induce P450 pathways of MYQORZO (eg, rifampin, moderate-to-strong CYP3A inducers) may lead to decreased blood concentrations of aficamten and potential loss of effectiveness. Assess LVEF 2 to 8 weeks after initiation of such inhibitors or after discontinuation of such inducers and adjust the dose of MYQORZO accordingly.
Advise patients of the potential for drug interactions. Advise patients to inform their healthcare provider of all concomitant medications prior to and during MYQORZO treatment.
ADVERSE REACTIONS
Hypertension was the only adverse reaction occurring in >
INDICATIONS AND USAGE
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
Please see full Prescribing Information approved in the U.S., including Boxed WARNING.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.
HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately one out of 350 individuals worldwide.3
Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).4
People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.5 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.6 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.
References
- Garcia-Pavia, P, et al. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025
- Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424
- Tsenov et al. Healthcare access, symptom burden, and psychological impact in hypertrophic cardiomyopathy: a multinational patient-driven survey. Int J Cardiol Cardiovasc Risk Prev2025 Aug 4;27:200485. doi:10.1016/j.ijcrp.2025.200485.
- Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552.
- Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
- Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the FDA approve for Cytokinetics’ MYQORZO label?
The FDA approved adding Phase 3 MAPLE-HCM data comparing MYQORZO and metoprolol, each used alone, to the U.S. prescribing information. MYQORZO’s indication remains treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
What did MYQORZO show in the MAPLE-HCM trial?
MYQORZO met the primary endpoint of change in peak oxygen uptake from baseline to Week 24 and significantly improved five of six secondary endpoints compared with metoprolol. Overall adverse-event rates were similar, while hypertension occurred in 15% of MYQORZO patients versus 3% receiving metoprolol.